Skip to main content
Pfizer pays $330 million for Starna's CAR-T programs
Image for illustrative purposes only. Not a real photo.

Pfizer pays $330 million for Starna's CAR-T programs

By

Key points

  • Pfizer (NYSE:PFE) signed an exclusive licensing agreement with Starna Therapeutics, securing rights outside Greater China to develop three experimental in vivo CAR-T programs targeting autoimmune diseases.
  • Starna will receive $330 million upfront and could earn up to $2.3 billion in development and commercial milestone payments, plus royalties on approved product sales.
  • Pfizer will lead clinical development and manufacturing outside Greater China, expanding its RNA medicine and immunology pipeline into next-generation cell therapies.

Pfizer (NYSE:PFE) entered an exclusive licensing agreement with Starna Therapeutics to develop, manufacture and commercialize three experimental in vivo chimeric antigen receptor T-cell (CAR-T) programs targeting autoimmune diseases outside Greater China.

The three programs are at the pre-investigational new drug (pre-IND) stage, meaning they have not yet entered human clinical trials, and form part of Starna's RNA-based medicine development portfolio.

"In vivo CAR-T is an emerging and promising approach for treating autoimmune diseases, and the patients who might benefit most are those for whom today's options fall short," said Michael Vincent, M.D., Ph.D., Pfizer's chief inflammation and immunology officer.

Under the agreement, Starna will receive $330 million upfront and could earn up to $2.3 billion in development and commercial milestone payments, plus royalties on net sales of approved products, while Pfizer will lead clinical development and manufacture initial clinical trial products at its US facilities.

Pfizer will also receive rights to use Starna's proprietary in vivo CAR-T technology in inflammation and immunology, as well as oncology, expanding its research into RNA-based medicines and cell therapies.

Starna's technology combines RNA therapeutics with targeted lipid nanoparticle (LNP) delivery systems designed to transport genetic medicines into specific tissues, while the agreement includes options for additional research programs and potential expansion of Pfizer's rights into Greater China.


Frequently asked questions